AKT1 and ovarian cancer: In this study, we show that LSD1 inhibitors markedly suppressed another major cancer-promoting pathway, PI3K/AKT signaling, in androgen-dependent PCa and CRPC cells, a consistent finding with a study using LSD1 inhibitor S2101 in an ovarian cancer cell line (35).